The Medicines Company has launched a new twelve hour formulation for the FDA approved Cleviprex Injectable Emulsion.Cleviprex is an intravenous dihydropyridine calcium channel blocker, which helps in reduction of blood pressure when oral therapy is not feasible. According to the company, the new formulation triples the maximum allowable infusion time per vial, known as hang time to 12 hours against the previous 4-hour hang time vial.The longer hang time which requires fewer vial changes, was achieved by adding a bacterial growth retardant.The Medicines Company senior vice president and chief customer officer Brent Furse said Cleviprex which needs fewer vial changes would help in the reduction of medication waste and provide an efficient, economical solution.
Related stories
AstraZeneca Advances AI Drug Discovery Deal with insitro
Identifying Sex Specific Outcomes Through Real-World Data Analysis
Strengthening Clinical Evidence Through Female Cohort Representation
World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.
Our 2026 Media Pack offers integrated solutions to reach your audience:
- Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
- Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
- Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Latest stories
Related stories
AstraZeneca Advances AI Drug Discovery Deal with insitro
Identifying Sex Specific Outcomes Through Real-World Data Analysis
Strengthening Clinical Evidence Through Female Cohort Representation
Advancing Menopause Treatments Through Hormonal Pathway Research
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access theMedia Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
